파로스백신

Foot-and-Mouth Disease
Bivalent Recombinant Protein Oil Vaccine

PharoVax^® FMD

• Approval Number

  Number 361 - 1

• Efficacy/Effectiveness

  Prevention of foot-and-mouth disease in pigs and cows
  Concurrent prevention of foot-and-mouth disease serotype O and serotype A

• Dosage

  2 mL at each inoculation per pig or cow

• Direction

  Initial immunization

  Primary inoculation is recommended on 8 weeks after birth in pigs and 4 months after birth in cows, intramuscularly.
  Second inoculation must be performed in the same manner after 4 weeks of primary inoculation.

  Additional immunization

  Inoculate every 6 months.
  In the event of a foot-and-mouth disease breakout, additional immunization is recommended regardless of schedule.

• Characteristics and Advantages

  PharoVax-FMD is a marker vaccine.

  It is a vaccine that uses recombinant proteins as the immunogen, and cannot lead to any antibodies against non-structural proteins (NSP). Therefore, it is possible the differential diagnosis of animals that have been immunized by the vaccine or that have been infected by field virus.

  PharoVax-FMD can be easily optimized for each region or country.

  Vaccines for newly mutated viral strains can be developed within 2 to 3 months. Also, one product can be expanded to defend against various serotypes or lineages of foot-and-mouth disease viruses. Therefore, optimized vaccines can be provided for various types of foot-and-mouth disease viruses adapted to specific countries or regions.